Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluocinolone acetonide implant (Medidur) in exudative AMD
NCT00605423Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Jan 2008
- Primary completion
- Nov 2011
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of fluocinolone in exudative age-related macular degeneration (2 arms), sponsored by Johns Hopkins University. Primary endpoint: Mean Change From Baseline in Visual Acuity at 6 months. Started Jan 2008; status: completed.
02
Drugs
fluocinolone
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT00605423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00605423.